Rectal Cancer
Conditions
Keywords
Rectal Cancer, Radiotherapy, High Risk, Total Neoadjuvant Therapy
Brief summary
A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Detailed description
Recommended treatment of patients with locally advanced rectal cancer (LARC) includes preoperative chemoradiation (CRT), total mesorectal excision (TME) and postoperative adjuvant chemotherapy (ACT). However, treatments fail to show an improved therapeutic effect on high-risk patients now. Total neoadjuvant therapy (TNT) is a new try for rectal cancer treatment,and this trial aims to identify and select the more promising TNT sequence. This trail is a multicenter, randomized, phase II trial . Eligible patients age from 18 to 75 years with histologically confirmed rectal adenocarcinoma. MRI is mandatory, and patients of stage II or III rectal cancer are eligible if any of the following criteria are fulfilled: Categories T4,Categories N2, MRF involvement, EMVI positive, and lateral lymph node involvement. Patients are randomly assigned to 3 groups, group 1: concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group);or group 2: concurrent chemoradiotherapy → consolidation chemotherapy → TME (CNCT group);Or group 3: induction chemotherapy → concurrent chemoradiotherapy →TME ( INCT group).The primary end point is the rate of tumor down-staging, which is defined as stage yp0-II after surgery,and watch-and-wait strategy after complete clinical response (cCR) was allowed. Secondary end points include acute toxicity, compliance with TNT, surgical complications, 3-year overall survival (3yOS),3-year disease free survival (3yDFS),3-year distant metastatic free survival(3yDMFS),3-year locoregional recurrence-free survival(3yLRRFS) and quality of life.
Interventions
COMBINATION_PRODUCTConcurrent Chemoradiotherapy
Radiotherapy: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d
DRUGXELOX
Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses，3 weeks per course
DRUGmFOLFOX
Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
PROCEDURETME
Total mesorectal excision
Sponsors
Peking University Cancer Hospital & Institute
Peking Union Medical College Hospital
Jilin Provincial Tumor Hospital
Cancer Hospital of Guizhou Province
Xijing Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. 18-75 years old, regardless of gender 2. Histologically confirmed rectal adenocarcinoma; 3. Up to 12 cm above the anal verge on the basis of rigid rectoscopy. 4. MRI of the rectum is acceptable; 5. Patients in stage II or III rectal cancer are eligible if any of the following criteria are fulfilled: Categories T4,Categories N2, MRF involvement, EMVI positive, and lateral lymph node involvement. 6. ECOG score 0-1 or KPS score ≥80.
Exclusion criteria
1. History of malignant tumor in other parts; 2. Cannot complete MRI; Allergic to 5-fu drugs; Allergic to platinum drugs; 3. During thrombolytic and anticoagulant therapy, the patient has bleeding diathesis or coagulation dysfunction; Or aneurysm, stroke, transient ischemic attack, arteriovenous malformation in the past year; 4. History of kidney, urine test found proteinuria or clinical renal function was significantly abnormal; 5. History of digestive tract fistula, perforation or severe ulcer; 6. Active infection is present; Clinically obvious heart disease; New York heart association (NYHA) of Ⅱ level or congestive heart failure; Unstable symptomatic arrhythmia or peripheral vascular disease ≥ grade II; Myocardial infarction and cerebrovascular accident occurred within 6 months before enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The rate of tumor down-staging | 6-8 months | Tumor down-staging is considered as Stage yp0-II after surgery, and watch-and-wait strategy after complete clinical response (cCR) was allowed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of surgical complications | 6-8 months | Incidence of surgical complications |
| Rate of compliance with TNT | 6-8 months | Rate of compliance with TNT |
| 3y OS | 3years | 3-year overall survival (3yOS) |
| 3y DFS | 3years | 3-year disease free survival (3yDFS) |
| CTCAE 4.0 | 6-8months | Severe acute adverse reaction rate（≥III degree） |
| 3y LRRFS | 3 years | 3-year locoregional recurrence-free survival(3yLRRFS) |
| EORTC QLQ-C30 | 3 years | EORTC QLQ-C30 to assess the quality of life |
| EORTC QLQ-CR29 | 3 years | EORTC QLQ-CR29 to assess the quality of life |
| Wexner continence grading scale | 3 years | Wexner continence grading scale |
| 3y DMFS | 3 years | 3-year distant metastatic free survival(3yDMFS) |
Countries
China
Outcome results
None listed